Aeon Biopharma, INC

AEON Biopharma, Inc. announced the completion of its public offering, including the partial exercise of an over-allotment option, raising additional capital.

Aeon Biopharma announced the pricing of its underwritten public offering, raising up to $13.75 million with potential for additional future funding through milestone warrants.

AEON Biopharma reported Q1 2026 results, highlighting positive FDA feedback on its biosimilar development strategy for ABP-450 and a significant reduction in outstanding debt.

AEON Biopharma reported a 2025 net loss while highlighting positive FDA feedback and analytical data for its ABP-450 Botox biosimilar, plus a $6M PIPE and note exchange to strengthen liquidity.

AEON Biopharma shareholders approve key transactions, including a debt-reducing note exchange and a PIPE financing, while the company progresses its ABP-450 biosimilar with a recent FDA meeting.

AEON Biopharma, Inc. unveils its strategy to introduce ABP-450 as a biosimilar to BOTOX, aiming for full label parity and significant market disruption by 2030.

AEON Biopharma reported continued operating losses and a strategic pivot to a Botox biosimilar pathway, securing new financing while addressing going concern doubts and NYSE American listing compliance.

AEON Biopharma reported a strategic shift to a biosimilar pathway for ABP-450, raised $18.3M in a public offering, and faces a going concern warning despite improved cash position.

AEON Biopharma, Inc. filed an Amendment No. 1 to its Quarterly Report on Form 10-Q for the period ended March 31, 2025, solely to include a previously omitted exhibit related to an amendment to its Amended and Restated Bylaws.

AEON Biopharma reports a net income for Q1 2025, driven by fair value adjustments, while navigating strategic changes and substantial doubt about its ability to continue as a going concern.

AEON Biopharma's Q3 2024 results show a net loss, a strategic shift to a biosimilar pathway for ABP-450, and ongoing efforts to secure additional funding.

AEON Biopharma announced its Q2 2024 results, highlighted by a strategic shift to pursue a biosimilar regulatory pathway for its lead product candidate, ABP-450.

AEON Biopharma, Inc. reports significant losses and going concern doubt in its 2025 annual filing, while advancing its ABP-450 botulinum toxin biosimilar program with positive analytical study results and strategic financing efforts.

AEON Biopharma, Inc. has filed an amendment to its 2024 Annual Report on Form 10-K to include inadvertently omitted corporate governance documents, specifically related to its Certificate of Incorporation and Bylaws, without altering any financial or other previously reported information.

AEON Biopharma's latest 10-K filing highlights a strategic pivot towards a biosimilar regulatory pathway for ABP-450, while also acknowledging substantial doubt about the company's ability to continue as a going concern due to ongoing losses and the need for additional financing.

AEON Biopharma has filed an amendment to its annual report to include exhibits that were inadvertently omitted in the original filing.

AEON Biopharma files an amended annual report restating its 2023 financials due to an accounting error related to acquired research and development, and expresses substantial doubt about its ability to continue as a going concern.

AEON Biopharma's annual 10-K filing highlights concerns about its ability to continue as a going concern, despite ongoing clinical trials for its lead product candidate, ABP-450.

AEON Biopharma's Chief Financial Officer, John Bencich, acquired 754,717 restricted stock units on April 2, 2026, as part of a long-term incentive plan.

AEON Biopharma's CLO, CSO, and Corporate Secretary, Alexander Blair Wilson, reported significant restricted stock unit awards, increasing his direct beneficial ownership.

AEON Biopharma's Principal Accounting Officer, Jennifer Sy, increased her beneficial ownership through significant restricted stock unit grants and modifications.

AEON Biopharma's President and CEO, Robert E. Bancroft, was granted 3,000,000 restricted stock units, vesting over four years.

AEON Biopharma, Inc. announced that Director Shelley B. Thunen was granted 308,641 Restricted Stock Units (RSUs) as part of her compensation, vesting fully on May 21, 2026.

AEON Biopharma, Inc.'s Executive Vice President, Chief Legal Officer, and Corporate Secretary, Alexander Blair Wilson, was granted 1,316,872 Restricted Stock Units as part of executive compensation.

AEON Biopharma, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, detailing proposals for director elections and auditor ratification.

AEON Biopharma, Inc. is calling a Special Meeting of Stockholders on January 21, 2026, to approve a private placement, an exchange of convertible notes, and an amended equity incentive plan, all crucial for funding the development of ABP-450 as a biosimilar to BOTOX.

AEON Biopharma announced positive biosimilarity data for ABP-450, strategic financing, and extended cash runway into Q2 2026, alongside its Q3 2025 financial results.

AEON Biopharma announced up to $22 million in funding through a private placement and a debt-to-equity exchange with Daewoong, significantly strengthening its balance sheet and accelerating its ABP-450 biosimilar program.

AEON Biopharma, Inc. has filed a supplement to its proxy statement to correct an inadvertently stated quorum requirement for its upcoming 2025 Annual Meeting of Stockholders.

AEON Biopharma, Inc. is holding its 2025 Annual Meeting of Stockholders on June 13, 2025, to elect directors and ratify the appointment of its independent auditor.

AEON Biopharma, Inc. files an S-1MEF to increase its public offering size by $4,528,125, including over-allotment options.

AEON Biopharma, Inc. has filed an amendment to its S-1 registration statement, primarily to update the filing fee table related to its proposed stock offering.

AEON Biopharma, Inc. has filed a registration statement for a proposed offering of Class A common stock, pre-funded warrants, and milestone warrants.

AEON Biopharma shifts strategy to pursue a biosimilar pathway for ABP-450, aiming for FDA approval across multiple therapeutic indications and registering securities for potential resale.

AEON Biopharma is seeking to register the resale of a substantial number of its common stock and warrants, as well as shares issuable upon exercise of existing warrants and options.

AEON Biopharma files for a potential $357 million resale of common stock and warrants, while also eyeing potential capital from warrant exercises.

Daewoong Co., Ltd. and Daewoong Pharmaceutical Co., Ltd. have increased their beneficial ownership in AEON Biopharma, Inc. to 49.99% through an exchange of convertible notes for common stock, a new note, and warrants.

Daewoong Co., Ltd. and Daewoong Pharmaceutical Co. Ltd. report their beneficial ownership in AEON Biopharma, Inc. has fallen below 1% due to recent dilution and a reverse stock split.

Robert J. Palmisano and The Palmisano Family, LLC have filed an amended Schedule 13D, revealing a beneficial ownership of 2,265,000 shares, representing approximately 5.7% of AEON Biopharma, Inc.'s Class A Common Stock.

Robert J. Palmisano, a director of AEON Biopharma, Inc., and The Palmisano Family, LLC, have disclosed beneficial ownership of 2,265,000 shares, representing a 5.7% stake in the company's Class A Common Stock.

Stonepine Capital Management, LLC and its affiliates have reported a 9.9% beneficial ownership in AEON Biopharma, Inc. Class A Common Stock.

Alta Partners LLC has reported a 2.1% beneficial ownership stake in AEON Biopharma, Inc., including shares from warrants, as detailed in its latest Schedule 13G amendment.

Alta Partners LLC has disclosed a beneficial ownership of 5.17% of AEON Biopharma, Inc.'s common stock, totaling 586,335 shares.

Jorey Chernett has filed a Schedule 13G, revealing a significant beneficial ownership of 9.98% in AEON Biopharma, Inc., holding 1,128,500 shares of common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, revealing a substantial reduction in its beneficial ownership of AEON Biopharma, Inc.'s Class A Common Stock to 4.11%.

S.H.N. Financial Investments Ltd. has reported a complete divestment of its beneficial ownership in AEON Biopharma, Inc.'s Class A Common Stock, reducing its stake from 5,400,000 shares to 0 shares.